FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173979771> ?p ?o ?g. }

• W3173979771 abstract "Background: Inhibition of the WEE1 kinase by adavosertib (AZD1775) potentiates replicative stress from genomic instability or chemotherapy, and demonstrated anti-tumor activity in preclinical models of pediatric cancer. This study reports the phase 2 expansion of the ADVL1312 phase I/II trial combining irinotecan and adavosertib in children and adolescents with relapsed/refractory solid and CNS tumors. Methods: Patients (< 21 yrs old) with measurable or MIBG-evaluable relapsed/refractory neuroblastoma (Part B), medulloblastoma/CNS embryonal tumors (Part C) or rhabdomyosarcoma (Part D) were treated with irinotecan (90 mg/m2/dose) and adavosertib (85 mg/m2/dose) orally for 5-days every 21-days. Any patient who received at least one dose was considered evaluable for response. Using a Simon's two stage design the combination was considered effective if there were three out of twenty responses in parts B and D or six out of nineteen responses in part C. Tumor tissue was analyzed for ATRX deficiency by multiplex immunofluorescence of ultrabright telomere foci and ATRX, and where available, prior tumor genomic analyses. Results: Twenty eligible patients with neuroblastoma, with a median age of nine years old (6-19) were included in Part B. They had a median of three prior chemotherapy regimens (1-7); nineteen patients (95%) had prior irinotecan and seventeen (85%) received prior radiation therapy. The combination therapy resulted in three objective responses confirmed by central review (estimated response rate of 16.7%) meeting the protocol defined efficacy endpoint for Part B. The responses included a measurable partial response (11 cycles), MIBG evaluable complete response (9 cycles) and MIBG and marrow evaluable partial response (18 cycles). In addition, there were three patients with prolonged stable disease of 8, 11 and 13 cycles. Two of the three patients with objective responses had tumors with predicted ATRX deficiency, while the third did not have available archival tumor. Of the nine neuroblastoma patient tumors with predicted ATRX deficiency, 4 (44%) had objective responses or prolonged stable disease. In part C, of 9 patients eligible for response, 1 patient with pineoblastoma had a confirmed partial response (9 cycles) and another with medulloblastoma had prolonged stable disease (11 cycles). In part D, of 10 eligible patients, 2 had stable disease of 8 and 10 cycles. Part C and D did not meet the protocol defined efficacy endpoint. The combination was well tolerated with one patient experiencing a dose limiting toxicity that resolved with dose reduction. Conclusion: This the first phase 2 clinical trial of adavosertib in pediatrics and the first in combination with irinotecan. The combination was of sufficient activity to support further study in neuroblastoma, and possibly other pediatric tumor types with recurrent ATRX mutation.Citation Format: Kristina A. Cole, Heba Ijaz, Lea Surrey, Mariarita Santi-vicini, Xiaowei Liu, Charles G. Minard, John M. Maris, Stephan Voss, Elizabeth Fox, Brenda Weigal. Pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children's Oncology Group Study (ADVL1312) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT029." @default.
• W3173979771 created "2021-07-05" @default.
• W3173979771 creator A5005796905 @default.
• W3173979771 creator A5005797590 @default.
• W3173979771 creator A5007563936 @default.
• W3173979771 creator A5032126905 @default.
• W3173979771 creator A5039619103 @default.
• W3173979771 creator A5046174386 @default.
• W3173979771 creator A5050738935 @default.
• W3173979771 creator A5060845977 @default.
• W3173979771 creator A5061833622 @default.
• W3173979771 creator A5064478563 @default.
• W3173979771 date "2021-07-01" @default.
• W3173979771 modified "2023-10-14" @default.
• W3173979771 title "Abstract CT029: Pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children's Oncology Group Study (ADVL1312)" @default.
• W3173979771 doi "https://doi.org/10.1158/1538-7445.am2021-ct029" @default.
• W3173979771 hasPublicationYear "2021" @default.
• W3173979771 type Work @default.
• W3173979771 sameAs 3173979771 @default.
• W3173979771 citedByCount "1" @default.
• W3173979771 countsByYear W31739797712022 @default.
• W3173979771 crossrefType "proceedings-article" @default.
• W3173979771 hasAuthorship W3173979771A5005796905 @default.
• W3173979771 hasAuthorship W3173979771A5005797590 @default.
• W3173979771 hasAuthorship W3173979771A5007563936 @default.
• W3173979771 hasAuthorship W3173979771A5032126905 @default.
• W3173979771 hasAuthorship W3173979771A5039619103 @default.
• W3173979771 hasAuthorship W3173979771A5046174386 @default.
• W3173979771 hasAuthorship W3173979771A5050738935 @default.
• W3173979771 hasAuthorship W3173979771A5060845977 @default.
• W3173979771 hasAuthorship W3173979771A5061833622 @default.
• W3173979771 hasAuthorship W3173979771A5064478563 @default.
• W3173979771 hasConcept C104317684 @default.
• W3173979771 hasConcept C121608353 @default.
• W3173979771 hasConcept C126322002 @default.
• W3173979771 hasConcept C142424586 @default.
• W3173979771 hasConcept C142724271 @default.
• W3173979771 hasConcept C143998085 @default.
• W3173979771 hasConcept C203092338 @default.
• W3173979771 hasConcept C2776689207 @default.
• W3173979771 hasConcept C2776694085 @default.
• W3173979771 hasConcept C2776715637 @default.
• W3173979771 hasConcept C2778256501 @default.
• W3173979771 hasConcept C2780259306 @default.
• W3173979771 hasConcept C2780789225 @default.
• W3173979771 hasConcept C2780844630 @default.
• W3173979771 hasConcept C2993561819 @default.
• W3173979771 hasConcept C501734568 @default.
• W3173979771 hasConcept C526805850 @default.
• W3173979771 hasConcept C535046627 @default.
• W3173979771 hasConcept C54355233 @default.
• W3173979771 hasConcept C55493867 @default.
• W3173979771 hasConcept C71924100 @default.
• W3173979771 hasConcept C81885089 @default.
• W3173979771 hasConcept C86803240 @default.
• W3173979771 hasConcept C87355193 @default.
• W3173979771 hasConceptScore W3173979771C104317684 @default.
• W3173979771 hasConceptScore W3173979771C121608353 @default.
• W3173979771 hasConceptScore W3173979771C126322002 @default.
• W3173979771 hasConceptScore W3173979771C142424586 @default.
• W3173979771 hasConceptScore W3173979771C142724271 @default.
• W3173979771 hasConceptScore W3173979771C143998085 @default.
• W3173979771 hasConceptScore W3173979771C203092338 @default.
• W3173979771 hasConceptScore W3173979771C2776689207 @default.
• W3173979771 hasConceptScore W3173979771C2776694085 @default.
• W3173979771 hasConceptScore W3173979771C2776715637 @default.
• W3173979771 hasConceptScore W3173979771C2778256501 @default.
• W3173979771 hasConceptScore W3173979771C2780259306 @default.
• W3173979771 hasConceptScore W3173979771C2780789225 @default.
• W3173979771 hasConceptScore W3173979771C2780844630 @default.
• W3173979771 hasConceptScore W3173979771C2993561819 @default.
• W3173979771 hasConceptScore W3173979771C501734568 @default.
• W3173979771 hasConceptScore W3173979771C526805850 @default.
• W3173979771 hasConceptScore W3173979771C535046627 @default.
• W3173979771 hasConceptScore W3173979771C54355233 @default.
• W3173979771 hasConceptScore W3173979771C55493867 @default.
• W3173979771 hasConceptScore W3173979771C71924100 @default.
• W3173979771 hasConceptScore W3173979771C81885089 @default.
• W3173979771 hasConceptScore W3173979771C86803240 @default.
• W3173979771 hasConceptScore W3173979771C87355193 @default.
• W3173979771 hasLocation W31739797711 @default.
• W3173979771 hasOpenAccess W3173979771 @default.
• W3173979771 hasPrimaryLocation W31739797711 @default.
• W3173979771 hasRelatedWork W1571073982 @default.
• W3173979771 hasRelatedWork W1992475224 @default.
• W3173979771 hasRelatedWork W2007539997 @default.
• W3173979771 hasRelatedWork W2014811174 @default.
• W3173979771 hasRelatedWork W2018887623 @default.
• W3173979771 hasRelatedWork W2030363482 @default.
• W3173979771 hasRelatedWork W2080583642 @default.
• W3173979771 hasRelatedWork W2084081269 @default.
• W3173979771 hasRelatedWork W3173979771 @default.
• W3173979771 hasRelatedWork W4366603213 @default.
• W3173979771 isParatext "false" @default.
• W3173979771 isRetracted "false" @default.
• W3173979771 magId "3173979771" @default.
• W3173979771 workType "article" @default.